ClinicalTrials.gg
CompletedNCT07932990Updated Nov 12, 2026

Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal Women

An interventional study of Halova vaginal ovules and Estriol 0.5 mg vaginal ovules in Genitourinary Syndrome of Menopause (GSM), Vaginal Dryness and Vulvo Vaginal Atrophy (VVA), sponsored by Perfect Care Distribution. Completed at 1 site in Romania. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Perfect Care Distribution · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Mar 2025, registered Nov 2026).
Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
252
Allocation
Non-randomized
Sex
Female
01

Study summary

The goal of this clinical study was to compare Halova vaginal ovules, a non-hormonal medical device, with vaginal estriol 0.5 mg, an estrogen treatment, for genitourinary symptoms in postmenopausal women.

The main questions were:

  • How do the treatments compare in reducing bothersome symptoms and improving vaginal health?
  • How do the treatments affect sexual function?
  • What medical problems and changes in the thickness of the lining of the uterus occur during the study?
  • Are improvements maintained after treatment has ended? Women willing to receive either treatment were randomly assigned to Halova or estriol in a 1:1 ratio. Women who declined hormonal therapy received Halova without randomization. Participants knew which treatment they received, while the clinicians assessing clinical outcomes did not know their treatment assignment.

Participants:

  • Used one vaginal ovule daily for the first two weeks, then one ovule twice weekly until the end of the 12-week treatment period.
  • Attended assessments at baseline, Week 12, and Week 24 for symptoms, vaginal health, sexual function, safety, and the thickness of the lining of the uterus.
  • Received telephone monitoring at Weeks 2, 4, and 8 for treatment use, tolerability, medical problems, and satisfaction.
  • Received individualized menopause-related education and written materials, and completed a questionnaire about knowledge, attitudes, and behaviors at baseline and Week 12.
Read the detailed description

This completed, single-center, post-market clinical study compared Halova vaginal ovules with Ovestin vaginal ovules containing estriol 0.5 mg in women with postmenopausal genitourinary symptoms. The study combined randomized and nonrandomized allocation according to participants' acceptance of hormonal therapy.

Women willing to receive either intervention were randomized 1:1 to Halova or estriol using computer-generated permuted blocks of four. Women who declined hormonal therapy were assigned directly to Halova. The study enrolled 252 participants: 55 randomized to Halova, 56 randomized to estriol, and 141 assigned directly to Halova. Overall, 196 participants received Halova and 56 received estriol.

The main comparative clinical analyses in the study report used the randomized subset of 111 participants. Analyses of the full cohort provided supportive information on clinical outcomes and tolerability. Participants assigned directly to Halova were analyzed separately from the randomized Halova group for the main treatment comparison.

Both interventions followed the same 12-week administration schedule: one ovule intravaginally daily for the first two weeks, followed by one ovule twice weekly until Week 12. Participants were aware of their treatment because the formulations and primary packaging differed. Clinical outcome assessors were blinded to treatment assignment. Treatment packs and educational materials were prepared by personnel who did not perform the clinical assessments.

Clinical assessments were performed at baseline, Week 12, and Week 24. The primary outcomes at Week 12 were changes in the Most Bothersome Symptom score, the study-adapted Vaginal Health Index total score, and its ordinal pH component score. Follow-up at Week 24 assessed persistence of treatment effects. Sexual function was evaluated using the Female Sexual Function Index. Endometrial thickness was assessed by transvaginal ultrasound at baseline, Week 12, and Week 24.

Safety was assessed in all treated participants through documentation of adverse events during clinical visits and telephone monitoring. Telephone contacts at Weeks 2, 4, and 8 also assessed adherence, tolerability, and satisfaction.

All participants received the same individualized educational counseling and written menopause-related materials. A study-specific knowledge, attitudes, and behaviors questionnaire was administered at baseline before counseling and again at Week 12. The educational component was evaluated through a before-and-after assessment within the cohort; there was no separate group that did not receive education.

02

Conditions studied

  • Genitourinary Syndrome of Menopause (GSM)
  • Vaginal Dryness
  • Vulvo Vaginal Atrophy (VVA)

Keywords

  • Postmenopause
  • Hyaluronic Acid
  • Sodium Hyaluronate
  • Xylitol
  • Estriol
  • Vaginal Health
  • Vaginal pH
  • Dyspareunia
  • Female Sexual Function
  • Non-hormonal Treatment
  • Patient Preference
03

In context

Dyspareunia

159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.

This study's enrollment of 252 is above the median of 64 across 127 interventional studies indexed under Dyspareunia.

Browse Dyspareunia studies →

Lead sponsor

Perfect Care Distribution is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 45 to 65 years in natural menopause, or women with menopause induced by bilateral oophorectomy or hormonal suppression.
  • Symptoms of genitourinary syndrome of menopause.
  • A Most Bothersome Symptom (MBS) score from 3 to 8 on a numerical rating scale ranging from 0 to 10.
  • Cervical cytology reported as negative for intraepithelial lesion or (NILM) or atypical squamous cells of undetermined significance (ASC-US) within the previous six months.
  • Written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Known to the active substances or any of the study interventions.
  • Known, previous, or suspected breast cancer.
  • Known or suspected estrogen-dependent malignant tumors, such as endometrial cancer.
  • Undiagnosed genital bleeding.
  • Untreated endometrial hyperplasia.
  • Current or previous venous thromboembolism, including deep vein thrombosis or pulmonary embolism.
  • Known thrombophilic disorders, such as protein C, protein S, or antithrombin deficiency.
  • Acute or recent arterial thromboembolic disease, such as angina or myocardial infarction.
  • Acute liver disease or a history of liver disease until liver function tests have returned to normal.
  • Porphyria.
  • infection or other immunodeficiency.
  • Use of systemic menopausal hormone therapy within the previous three months.
  • Use of spermicides or a diaphragm during the study.
  • Absence of written .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Halova - Randomized

    Participants willing to receive either treatment who were randomized to Halova vaginal ovules. This arm included 55 participants.

    Device: Halova vaginal ovules · Behavioral: Menopause-related education and counseling

  • Active comparator
    Estriol - Randomized

    Participants willing to receive either treatment who were randomized to Ovestin vaginal ovules containing estriol 0.5 mg. This arm included 56 participants.

    Drug: Estriol 0.5 mg vaginal ovules · Behavioral: Menopause-related education and counseling

  • Experimental
    Halova - Direct Assignment

    Participants who declined hormonal therapy and were assigned directly to Halova vaginal ovules without randomization. This arm included 141 participants.

    Device: Halova vaginal ovules · Behavioral: Menopause-related education and counseling

Interventions

  • DeviceHalova vaginal ovules

    Halova is a vaginal medical device formulated as ovules containing sodium hyaluronate (5 mg per ovule) and xylitol (3 mg per ovule), together with semi-synthetic glycerides, lanolin, Aloe vera oil extract, Calendula officinalis extract, colloidal silicon dioxide, and vitamin E. One ovule was administered intravaginally daily for the first two weeks, followed by one ovule twice weekly until the end of the 12-week treatment period.

  • DrugEstriol 0.5 mg vaginal ovules

    Each Ovestin vaginal ovule contained estriol 0.5 mg. One ovule was administered intravaginally daily for the first two weeks, followed by one ovule twice weekly until the end of the 12-week treatment period.

  • BehavioralMenopause-related education and counseling

    All participants received individualized counseling and written educational materials about menopause, genitourinary symptoms, and available management options. A study-specific questionnaire was administered before the educational intervention at baseline and again at Week 12. This intervention was common to all three allocation arms.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Most Bothersome Symptom (MBS) Score at Week 12

    At baseline, each participant identified the genitourinary symptom causing the greatest discomfort, such as vaginal dryness, dyspareunia, or urinary symptoms. The same symptom was reassessed at Week 12 using an 11-point numerical rating scale from 0 (symptom absent) to 10 (maximum severity). Improvement was calculated as the baseline score minus the Week 12 score, with positive values indicating reduced symptom severity.

    Time frame: Baseline and Week 12

  2. Change From Baseline in Study-Adapted Vaginal Health Index (VHI) Total Score at Week 12

    Vaginal health was assessed using a study-adapted version of the Vaginal Health Index (VHI), as defined in the study-specific standardized clinical assessment guide. Five parameters were evaluated: vaginal elasticity, moisture, vaginal pH category, epithelial integrity, and inflammation. Each parameter was scored from 0 (severely impaired) to 5 (normal). The total score was the sum of the five component scores and ranged from 0 to 25, with higher scores indicating better vaginal health. Change was calculated as the Week 12 total score minus the baseline total score, with positive values indicating improvement.

    Time frame: Baseline and Week 12

  3. Change From Baseline in Vaginal pH Component Score of the Study-Adapted VHI at Week 12

    Vaginal pH was summarized using the ordinal pH component of the study-adapted VHI. Scores ranged from 0 to 5: 5 for pH 4.5 or lower; 4 for pH above 4.5 to 5.0; 3 for pH above 5.0 to 5.5; 2 for pH above 5.5 to 6.0; 1 for pH above 6.0 to 6.5; and 0 for pH above 6.5. Higher scores indicated a more favorable vaginal pH category. Change was calculated as the Week 12 component score minus the baseline score, with positive values indicating improvement. The analyzed outcome was the component score rather than the raw numerical pH value.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Female Sexual Function Index (FSFI) Total Score at Week 12

    Female sexual function was assessed using the 19-item Female Sexual Function Index (FSFI), covering desire, arousal, lubrication, orgasm, satisfaction, and pain. Total scores ranged from 2 to 36, with higher scores indicating better sexual function. Change was calculated as the Week 12 total score minus the baseline total score, with positive values indicating improvement. The main FSFI analysis included participants with calculable total scores; analysis restricted to participants sexually active at baseline was supplementary.

    Time frame: Baseline and Week 12

  2. Change From Baseline in Most Bothersome Symptom (MBS) Score at Week 24

    At baseline, each participant identified the genitourinary symptom causing the greatest discomfort, such as vaginal dryness, dyspareunia, or urinary symptoms. The same symptom was reassessed at Week 24 using an 11-point numerical rating scale from 0 (symptom absent) to 10 (maximum severity). Improvement was calculated as the baseline score minus the Week 24 score, with positive values indicating reduced symptom severity.

    Time frame: Baseline and Week 24

  3. Change From Baseline in Study-Adapted Vaginal Health Index (VHI) Total Score at Week 24

    Vaginal health was assessed using a study-adapted version of the Vaginal Health Index (VHI), as defined in the study-specific standardized clinical assessment guide. Five parameters were evaluated: vaginal elasticity, moisture, vaginal pH category, epithelial integrity, and inflammation. Each parameter was scored from 0 (severely impaired) to 5 (normal). The total score was the sum of the five component scores and ranged from 0 to 25, with higher scores indicating better vaginal health. Change was calculated as the Week 24 total score minus the baseline total score, with positive values indicating improvement.

    Time frame: Baseline and Week 24

  4. Change From Baseline in Vaginal pH Component Score of the Study-Adapted VHI at Week 24

    Vaginal pH was summarized using the ordinal pH component of the study-adapted VHI. Scores ranged from 0 to 5: 5 for pH 4.5 or lower; 4 for pH above 4.5 to 5.0; 3 for pH above 5.0 to 5.5; 2 for pH above 5.5 to 6.0; 1 for pH above 6.0 to 6.5; and 0 for pH above 6.5. Higher scores indicated a more favorable vaginal pH category. Change was calculated as the Week 24 component score minus the baseline score, with positive values indicating improvement. The analyzed outcome was the component score rather than the raw numerical pH value.

    Time frame: Baseline and Week 24

  5. Change From Baseline in Female Sexual Function Index (FSFI) Total Score at Week 24

    Female sexual function was assessed using the 19-item Female Sexual Function Index (FSFI), covering desire, arousal, lubrication, orgasm, satisfaction, and pain. Total scores ranged from 2 to 36, with higher scores indicating better sexual function. Change was calculated as the Week 24 total score minus the baseline total score, with positive values indicating improvement. The main FSFI analysis included participants with calculable total scores; analysis restricted to participants sexually active at baseline was supplementary

    Time frame: Baseline and Week 24

  6. Change From Baseline in Endometrial Thickness at Week 12

    Endometrial thickness was measured in millimeters by transvaginal ultrasound. Change was calculated as the Week 12 measurement minus the baseline measurement; positive values indicated increased thickness. The quantitative analysis included participants with measurable values greater than zero at both assessments. Zero values treated as not applicable in the context of an absent uterus were excluded from this continuous analysis. Clinically relevant individual findings were also documented in the safety record.

    Time frame: Baseline and Week 12

  7. Change From Baseline in Endometrial Thickness at Week 24

    Endometrial thickness was measured in millimeters by transvaginal ultrasound. Change was calculated as the Week 24 measurement minus the baseline measurement; positive values indicated increased thickness. The quantitative analysis included participants with measurable values greater than zero at both assessments. Zero values treated as not applicable in the context of an absent uterus were excluded from this continuous analysis. Clinically relevant individual findings were also documented in the safety record.

    Time frame: Baseline and Week 24

  8. Number of Participants With Adverse Events During the Study

    Safety was assessed by documenting adverse events reported by participants or identified during clinical assessments and telephone follow-up, regardless of the suspected relationship to treatment. The outcome was the number and percentage of treated participants experiencing at least one adverse event. Events were characterized by seriousness, severity, suspected relationship to the assigned intervention, action taken, and outcome. Safety summaries included all treated participants, with separate reporting for the randomized subset when appropriate.

    Time frame: From baseline through Week 24

  9. Change From Baseline in Item-Level Responses to a Menopause-Related Knowledge, Attitudes, and Behaviors Questionnaire at Week 12.

    Participants completed a study-specific questionnaire at baseline, before individualized educational counseling and receipt of written educational materials, and again at Week 12. The questionnaire assessed recognition of menopause-related symptoms, associated health risks, and management options, as well as perceptions and behaviors related to menopause. For each item, outcomes were the number and percentage of participants selecting each response option at baseline and Week 12, and the change in these percentages between assessments. For questions allowing multiple responses, each option was evaluated separately. No composite scoring algorithm was prespecified in the study protocol.

    Time frame: Baseline and Week 12

  10. Self-Reported Adherence to the Assigned Intervention at Week 2

    Adherence to the prescribed administration schedule was assessed from participant reports and recorded in the study case report form. The outcome was the number and percentage of participants documented as adherent at Week 2. The denominator was the number of participants with available adherence data at that assessment

    Time frame: Week 2

  11. Self-Reported Adherence to the Assigned Intervention at Week 4

    Adherence to the prescribed administration schedule was assessed from participant reports and recorded in the study case report form. The outcome was the number and percentage of participants documented as adherent at Week 4. The denominator was the number of participants with available adherence data at that assessment.

    Time frame: Week 4

  12. Self-Reported Adherence to the Assigned Intervention at Week 8

    Adherence to the prescribed administration schedule was assessed from participant reports and recorded in the study case report form. The outcome was the number and percentage of participants documented as adherent at Week 8. The denominator was the number of participants with available adherence data at that assessment

    Time frame: Week 8

  13. Self-Reported Adherence to the Assigned Intervention at Week 12

    Adherence to the prescribed administration schedule was assessed from participant reports and recorded in the study case report form. The outcome was the number and percentage of participants documented as adherent at Week 12. The denominator was the number of participants with available adherence data at that assessment.

    Time frame: Week 12

Other outcomes

  1. Participant-Reported Treatment Satisfaction at Week 12

    Participants reported overall treatment satisfaction using five response categories: very satisfied, satisfied, no opinion, dissatisfied, or very dissatisfied. The outcome was the number and percentage of evaluable participants in each response category at the end-of-treatment assessment. Positive satisfaction was summarized as the number and percentage selecting very satisfied or satisfied.

    Time frame: Week 12

07

Study locations

1 site
  • Arad County Clinical Emergency Hospital - Department of Obstetrics and Gynecology
    Arad, Romania
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual participant data. Study findings will be reported in aggregate form in scientific publications.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Apr 2026, 13 months.

Of 60 interventional studies with no phase under Dyspareunia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 38. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 12, 2026
StartActual
Mar 7, 2025
Primary completionActual
Apr 22, 2026
CompletionActual
Jun 22, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07932990
Lead sponsor
Perfect Care Distribution
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Mar 7, 2025
Primary completion
Apr 22, 2026
Completion
Jun 22, 2026
Last update
Nov 12, 2026

Study contacts

Cristian Furau, MD, PhD
principal investigator · Arad County Clinical Emergency Hospital; Vasile Goldis Western University of Arad
Delia Mirela Tit, PhD
study director · University of Oradea, Faculty of Medicine and Pharmacy, Romania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion